Biotechnology and Pharmaceuticals
Total Page:16
File Type:pdf, Size:1020Kb
Biotechnology and Pharmaceuticals in the Capital Region Berlin-Brandenburg Takeda‘s Oranienburg location – center of excellence for fixed The CoLaborator from Bayer provides the perfect environment for young forms in the worldwide production network companies in the life sciences. Biotech Leading European location for Analyticon Discovery »The technology for our innovative biotechnology BIOTECON Diagnostics vaccines originated at the Max Biotechnology is an engine of innovation in Planck Institute of Colloids and Co.don Interfaces which is located in the Epigenomics the Berlin-Brandenburg region. The sector is greater Berlin area. So it was natu- Glycotope recording steady growth and a high rate of ral to locate Vaxxilon in the region. Ifp Institut für Produktqualität We received excellent support from company startups. This positive trend is based the Adlershof Technology Park to In.vent DIAGNOSTICA on the region’s excellent research landscape establish our offices and laboratories.« InVivo Biotech Services and technology parks specialized in biotech- JPT Peptide Technologies Dr. Claney Pereira KNAUER nology. They provide optimal conditions for General Manager Wissenschaftliche Geräte startups and large, research-intensive compa- Vaxxilon Deutschland GmbH LGC nies alike. Of the more than 240 biotechnology metanomics companies with approx. 5,000 employees here, MOLOGEN NOXXON Pharma 80% focus on biomedicine. They develop inno- Omeicos Therapeutics vative therapeutic and diagnostic procedures Pharmaceutical location with a Organobalance for the treatment of cancer, cardiovascular rich history and modern dynamics ProBioGen diseases and diabetes, and benefit from the The sustained success of pharmaceutical in- Seramun Diagnostica region‘s excellent science and top infrastruc- dustry in Berlin and Brandenburg is based on SGS INSTITUT FRESENIUS Berlin ture for clinical studies. Berlin- Brandenburg innovative products and a venerable tradition SIFIN possesses expertise in genome and proteome reaching back to the 19th century. The sector Silence Therapeutics research, diagnostics, regenerative medicine, benefits from an excellent scientific environ- Thermo Fisher Scientific – RNA technologies and glyco- engineering ment and clinical research landscape, and its B·R·A·H·M·S TIB MOLBIOL technology. proximity to the health care system decision makers. This applies to global players such as For a complete overview Bayer, Pfizer, Sanofi, Takeda and Berlin-Che- of all the companies, mie (Menarini) and to more than see our Life Sciences »The Berlin-Brandenburg metropol- Report. itan area is a unique place inside 20 additional medium-sized pharmaceuticals the German healthcare sector. Nowhere else in Germany will you companies with a total of 10,000 employees. find a comparable concentration Many international corporations such as Daiichi of world class science, hospitals and industry. This cross-functional Sankyo and Astra Zeneca also have represent- cluster turns the German capital ative offices in Berlin. region into a true magnet for healthcare investments Bayer can look back at a long history in Berlin. in Europe.« Today, the company is one of the world‘s lead- Stefan Oelrich Member of the Board of Management ing speciality pharmaceuticals companies. President Pharmaceuticals More than 1,000 Sanofi employees manage Bayer AG the company‘s marketing and sales activities in Berlin. In 2011, Takeda Pharma took over the Nycomed Group and only one year later, moved its sales headquarters to Berlin. Take- da is currently investing €100 million to ex- pand its production facilities in Oranienburg. Leading German biotechnology location with over 240 companies in the sector Pharmaceutical location with a rich history Outstanding conditions for clinical research Excellent access to skilled specialists due to the many degree, training and continuing education programs Outstanding science landscape featuring Charité – Universitätsmedizin Berlin and many other university and non-university research institutions (Max Planck, Fraunhofer and Leibniz Institutes and the Helmholtz Centers) Political center and seat of the vfa, BPI and BIO Deutschland sector associations, as well as health insurance companies and patient organisations Production of biomarkers at B.R.A.H.M.S GmbH in Tight network among science and business through interdisciplinary partner- Hennigsdorf ships in the areas of biotechnology, diagnostics, pharmaceuticals, medical technology, photonics and ICT Pharmaceutical giant Pfizer is also expanding Pharma »The Berlin-Brandenburg region is Aenova / its activities in the capital region, establishing a leading location for healthcare in Haupt Pharma Berlin Germany. The proximity to science other business units to supplement its Ger- Aristo Pharma and research, and also to health man headquarters here. For example, the policy actors, make it the ideal Bausch + Lomb company manages its oncology business unit location for our sales center and Bayer one of our production facilities. In for Europe from Berlin. In 2014 Riemser Phar- Berlin-Chemie producing and distributing mostly (Menarini Group) ma reinforced its sales activities with an oper- speciality drugs, we employ over 1,000 workers DR. KADE ations-related unit in Berlin. In 2015 Boehringer and trainees in Berlin and Brandenburg.« Pharmazeutische Fabrik Ingelheim opened a representative office in Günter Kloucek Klosterfrau Berlin CEO Merz Pharmaceuticals the capital. Berlin-Chemie is investing € 80 Takeda Pharma Vertrieb GmbH & Co. KG Next Pharma million to expand its production facilities in the Pfizer south of Berlin. Dr. Kade, which has been Riemser Pharma growing in the capital region for over 25 years, Sanofi has taken over Takeda‘s OTC business. And Brandenburg facilitates all kinds of clinical Shire the fact that Klosterfrau Berlin invested in a research projects. Charité – Universitätsmedi- Takeda Pharma new production hall also shows that Berlin has zin Berlin and CROs such as Parexel – active Networks developed into an important production loca- with over 1,000 employees in Berlin – and BioResponse Network tion in recent years. other smaller providers that supervise studies DiagnostikNet-BB of all types all play outstanding roles in this area. glyconet Berlin Clinical research Brandenburg NetPhaSol The close connection between research, Optimal conditions for startups development and the clinics here is most The nine biotechnology parks in the region Biotech-Parks obviously demonstrated by the region‘s suc- provide optimal conditions for young, growing berlinbiotechpark cessful, well-established translational research companies. Over 50% of the biotechnology Biotech Campus Potsdam and the wide range of opportunities available companies use the programs of the state- Biotechnologiepark Luckenwalde for implementing clinical studies. With its large, owned or privately operated parks, which offer Campus Berlin-Buch extremely diverse patient collective, Berlin- a variety of contextual focal areas. In addition co:bios Technologiezentrum to the availability of laboratory space and an Hennigsdorf GO:IN Golm Innovations- »We founded OMEICOS Therapeu- extensive technical infrastructure, they benefit zentrum, Potsdam tics on the base of research results, from the close contact and intense exchange Science and Technology generated at the Max-Delbrück- Park Adlershof Center for Molecular Medicine. Our with the research institutions and multi- faceted continuous close collaboration with service providers that are also located in the Techno Terrain Teltow MDC and other partners in Berlin Wuhlheide Innovation Park is of great value for OMEICOS’ parks. success. As pioneers in the field of When it comes to early stage financing, the synthetic omega-3 epoxyeicosanoid analogs, we are developing small molecules for cardiovascular and states‘ own business development banks have ophthalmic indications.« investment companies whose technology Dr. Karen Uhlmann funds play an important role. Projects such as Director Legal Corporate & Operations Bayer‘s CoLaborator are evidence of the major OMEICOS Therapeutics GmbH pharmaceuticals corporations‘ involvement. Our aim: your success! Berlin and Brandenburg support the biotechnology and pharma focal area with an economic policy developed across state borders in the Healthcare industries cluster. The cluster is managed under the aegis of Berlin Partner for Business and Technology and the Brandenburg Economic Development Corporation. Our aim is to provide comprehensive support to companies and scientific institutions interested in inward investment or further development in the capital region. We are ready to assist you with: Company start-up Employee recruiting, Location search programs designed to retain Funding and financing skilled specialists and Technology transfer and R&D qualification partnerships International market Cooperating in networks development Reach out and contact us! www.healthcapital.de PHOTOS: Cover: YAZ-Flex production in Berlin, Bayer. Inside: Takeda/Sebastian Bolesch, Bayer, B•R•A•H•M•S DESIGN: Büro Watkinson, Berlin. PRINT: LASERLINE, Berlin © November 2018 EUROPEAN UNION Berlin Partner für Wirtschaft Wirtschaftsförderung und Technologie GmbH Land Brandenburg GmbH Publisher: Berlin Partner for Business and Techno- Fasanenstr. 85 Babelsberger Straße 21 logy in cooperation with the Brandenburg Economic 10623 Berlin 14473 Potsdam Development Corporation. Funded by the State of www.berlin-partner.de www.wfbb.de Berlin and the European Regional Development Twitter: @BerlinPartner Fund through the Investitionsbank Berlin. Contact: Contact: Carolin Clement Stefan Bauer T +49 30 46302 430 T +49 331 20029 253 [email protected] [email protected].